Camurus has announced a major expansion of its collaboration with Eli Lilly, extending the reach of its FluidCrystal drug delivery technology into a new therapeutic category. The development marks another milestone in the growing partnership between the two companies as they advance long-acting cardiometabolic diseases. The expanded agreement follows a collaboration launched that granted Lilly exclusive worldwide rights to develop and commercialize long-acting medicines using FluidCrystal technology and selected proprietary drug compounds.
Since then, both companies have worked to broaden the application of the platform across multiple therapeutic areas. Under the latest agreement, Lilly has exercised its option to include amylin receptor agonists in the collaboration. Consequently, the partnership now covers up to four proprietary Lilly compounds across three major drug classes. These include dual GLP-1 and GIP receptor agonists, triple agonists targeting GLP-1, GIP, and glucagon receptors, and amylin receptor agonists.
The decision significantly expands the potential applications of FluidCrystal technology within the rapidly growing cardiometabolic treatment market. Moreover, it reflects Lilly’s confidence in the long-acting delivery platform developed by Camurus.
According to the agreement, Lilly’s option exercise triggers an initial payment of $5 million. In addition, Camurus will continue to be eligible for making more payments related to development milestones, regulatory milestones, and commercial milestones. The arrangement includes up to $290 million in development and regulatory milestone payments, as well as up to $580 million in sales-based milestone payments. Furthermore, Camurus could receive tiered mid-single-digit royalties on future product sales.
Company executives emphasized the strategic importance of the expanded partnership. Camurus President and Chief Executive Officer Fredrik Tiberg stated that Lilly’s decision validates the company’s technology while extending FluidCrystal into the emerging field of amylin therapeutics. He also highlighted the progress achieved through the collaboration and the opportunities ahead.
The original partnership, established in 2025, focused on developing long-acting incretin therapies for cardiometabolic health. At that time, Lilly obtained the exclusive right to utilize FluidCrystal technology using up to four proprietary compounds. This was a timely decision given the growing demand for convenient treatments that improve convenience and patient adherence.
FluidCrystal technology has attracted growing industry attention because it enables controlled and sustained drug release after administration. The technology is able to convert injectable fluids into degradable depots that release the drugs over time. This means that FluidCrystal may decrease the dosage while improving treatment outcomes.
Industry observers view long-acting therapies as a critical growth area within obesity, diabetes, and broader cardiometabolic disease management. Therefore, the expansion of FluidCrystal in the area of amylin therapy is consistent with other pharmaceutical companies’ strategies for creating convenient solutions for patients.
Amylin receptor agonists have emerged as an important area of research because they may complement existing metabolic therapies and support weight management strategies. By adding this compound class to the collaboration, Lilly gains additional opportunities to leverage FluidCrystal technology across a broader range of drug candidates.
The expanded agreement strengthens Lilly’s exclusive global rights to apply FluidCrystal technology within the covered cardiometabolic programs. Meanwhile, Camurus benefits from enhanced commercial potential and additional milestone opportunities tied to future development success.
This partnership demonstrates a growing focus among pharmaceutical companies on long-acting drug delivery platforms. Several developers are seeking technologies that can improve patient adherence rates, simplify dosing regimens, and prolong efficacy periods. Therefore, FluidCrystal has emerged as a more valuable platform amid the competitive field of the cardiometabolic treatment landscape.
Camurus, a biopharmaceutical company focused on severe and chronic diseases, continues to expand the commercial reach of its proprietary technology. At the same time, Lilly is strengthening its pipeline of next-generation therapies targeting some of the world’s fastest-growing healthcare challenges.
The latest expansion demonstrates the growing confidence of major pharmaceutical companies in advanced drug delivery technologies. As healthcare practitioners continue looking for treatments that need less frequent administration, more long-term treatment platforms are expected to rise.
As the development programs continue, it is expected that both corporations will further exploit opportunities arising from their partnership. At this stage, the deal illustrates the growing strategic value of FluidCrystal technology in the future development of long-acting cardiometabolic drugs.
